Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3818322 | 0.98 | CYP1A2 (0.66) | CYP1A2TSHRALDH1A1CTSDL3MBTL1 | |
| SCHEMBL258598 | 0.82 | CYP1A2 (0.69) | CYP1A2TSHRALDH1A1CTSDL3MBTL1 | |
| SCHEMBL5853954 | 0.82 | ALDH1A1 (0.58) | CYP1A2TSHRALDH1A1CTSDMAPT | |
| SCHEMBL3051206 | 0.81 | CYP1A2 (0.68) | CYP1A2TSHRALDH1A1CTSDL3MBTL1 | |
| SCHEMBL7263686 | 0.81 | CYP1A2 (1.00) | CYP1A2TSHRALDH1A1CTSDL3MBTL1 | |
| SCHEMBL5583414 | 0.81 | CYP1A2 (0.68) | CYP1A2TSHRALDH1A1CTSDL3MBTL1 | |
| SCHEMBL7263695 | 0.81 | CYP1A2 (1.00) | CYP1A2TSHRALDH1A1CTSDL3MBTL1 | |
| SCHEMBL3259894 | 0.81 | CYP1A2 (0.68) | CYP1A2TSHRALDH1A1CTSDL3MBTL1 | |
| SCHEMBL10616251 | 0.80 | CYP1A2 (0.54) | CYP1A2TSHRALDH1A1MAPTGRM8 | |
| SCHEMBL1471179 | 0.80 | CYP1A2 (0.49) | CYP1A2TSHRALDH1A1CTSDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 699 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250354931-A1 | SPATIAL TARGETING OF ANALYTES | 10X GENOMICS INC (US) | 2025-11-20 | — | — | US | claimed |
| US-12399123-B1 | Spatial targeting of analytes | 10X GENOMICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-26 | — | — | US | claimed |
| CN-118019980-A | Peptide screening | 牛津大学科技创新有限公司 | 2024-05-10 | — | — | CN | claimed |
| EP-4348255-A1 | PEPTIDE SCREEN | Oxford University Innovation Limited (GB) | 2024-04-10 | — | — | EP | claimed |
| CN-117487028-A | Polypeptide for increasing antigen to tumor tissue and application thereof | 南开大学 | 2024-02-02 | — | — | CN | claimed |
| US-20230390335-A1 | SYNTHETIC ANTIGENS AS CHIMERIC ANTIGEN RECEPTOR (CAR) LIGANDS AND USES THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2023-12-07 | — | — | US | claimed |
| WO-2023178313-A2 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-21 | — | — | WO | claimed |
| EP-4204445-A2 | ASSAYS AND REAGENTS FOR CHARACTERIZATION OF MHCI PEPTIDE BINDING | GENENTECH, INC. (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116234813-A | Assays and reagents for characterizing MHCI peptide binding | 基因泰克公司 | 2023-06-06 | — | — | CN | claimed |
| US-20170145060-A9 | MEANS AND METHODS FOR BREAKING NONCOVALENT BINDING INTERACTIONS BETWEEN MOLECULES | HET NEDERLANDS KANKER INSTITUUT (NL) | 2017-05-25 | — | — | US | claimed |
| US-20150246952-A1 | MEANS AND METHODS FOR BREAKING NONCOVALENT BINDING INTERACTIONS BETWEEN MOLECULES | HET NL KANKER INST (NL) | 2015-09-03 | — | — | US | claimed |
| US-9079941-B2 | Means and methods for breaking noncovalent binding interactions between molecules | HET NEDERLANDS KANKER INSTITUUT (NL) | 2015-07-14 | — | — | US | claimed |
| CN-101146824-B | Means and methods for breaking non-covalent binding interactions between molecules | HET NL KANKER I | 2013-06-19 | — | — | CN | claimed |
| EP-1841791-B1 | MEANS AND METHODS FOR BREAKING NONCOVALENT BINDING INTERACTIONS BETWEEN MOLECULES | STICHTING NL KANKER INST (NL) | 2012-12-19 | — | — | EP | claimed |
| US-20080145378-A1 | Means and Methods for Breaking Noncovalent Binding Interactions Between Molecules | HET NEDERLANDS KANKER INSTITUUT (NL) | 2008-06-19 | — | — | US | claimed |
| CN-101146824-A | Means and methods for breaking non-covalent binding interactions between molecules | HET NL KANKER I (NL) | 2008-03-19 | — | — | CN | claimed |
| EP-1841791-A2 | MEANS AND METHODS FOR BREAKING NONCOVALENT BINDING INTERACTIONS BETWEEN MOLECULES | Het Nederlands Kanker Instituut (NL) | 2007-10-10 | — | — | EP | claimed |
| WO-2006080837-A2 | MEANS AND METHODS FOR BREAKING NONCOVALENT BINDING INTERACTIONS BETWEEN MOLECULES | HET NEDERLANDS KANKER INSTITUUT (NL) | 2006-08-03 | — | — | WO | claimed |
| EP-1683808-A1 | Means and methods for breaking noncovalent binding interactions between molecules | Het Nederlands Kanker Instituut (NL) | 2006-07-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | QPCT, SSTR5, SSTR4 | CYP1A2 1225/4885TSHR 84/4885ALDH1A1 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.